TY - JOUR
T1 - Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System
AU - Hanley, Patrick J.
AU - Mei, Zhuyong
AU - Durett, April G.
AU - da Graca Cabreira-Harrison, Marie
AU - Klis, Mariola
AU - Li, Wei
AU - Zhao, Yali
AU - Yang, Bing
AU - Parsha, Kaushik
AU - Mir, Osman
AU - Vahidy, Farhaan
AU - Bloom, Debra
AU - Rice, R. Brent
AU - Hematti, Peiman
AU - Savitz, Sean I.
AU - Gee, Adrian P.
N1 - Funding Information:
The authors would like to thank Terumo BCT as well as Dr Helen Heslop and Dr Malcolm Brenner for their guidance and support of this project. This work was funded by a Production Assistance for Cellular Therapy (PACT) contract from the NIH-NHLBI to Baylor College of Medicine Center for Cell and Gene Therapy, Contract No. HHSN268201000007C , as well as a Cancer Prevention Research Institute of Texas award RP110553 to Malcolm Brenner.
PY - 2014/8
Y1 - 2014/8
N2 - Background: The use of bone marrow-derived mesenchymal stromal cells (MSCs) as a cellular therapy for various diseases, such as graft-versus-host disease, diabetes, ischemic cardiomyopathy and Crohn's disease, has produced promising results in early-phase clinical trials. However, for widespread application and use in later phase studies, manufacture of these cells must be cost-effective, safe and reproducible. Current methods of manufacturing in flasks or cell factories are labor-intensive, involve a large number of open procedures and require prolonged culture times. Methods: We evaluated the Quantum Cell Expansion System for the expansion of large numbers of MSCs from unprocessed bone marrow in a functionally closed system and compared the results with a flask-based method currently in clinical trials. Results: After only two passages, we were able to expand a mean of 6.6× 108 MSCs from 25 mL of bone marrow reproducibly. The mean expansion time was 21 days, and cells obtained were able to differentiate into all three lineages: chondrocytes, osteoblasts and adipocytes. The Quantum was able to generate the target cell number of 2.0× 108 cells in an average of 9 fewer days and in half the number of passages required during flask-based expansion. We estimated that the Quantum would involve 133 open procedures versus 54,400 in flasks when manufacturing for a clinical trial. Quantum-expanded MSCs infused into an ischemic stroke rat model were therapeutically active. Conclusions: The Quantum is a novel method of generating high numbers of MSCs in less time and at lower passages when compared with flasks. In the Quantum, the risk of contamination is substantially reduced because of the substantial decrease in open procedures.
AB - Background: The use of bone marrow-derived mesenchymal stromal cells (MSCs) as a cellular therapy for various diseases, such as graft-versus-host disease, diabetes, ischemic cardiomyopathy and Crohn's disease, has produced promising results in early-phase clinical trials. However, for widespread application and use in later phase studies, manufacture of these cells must be cost-effective, safe and reproducible. Current methods of manufacturing in flasks or cell factories are labor-intensive, involve a large number of open procedures and require prolonged culture times. Methods: We evaluated the Quantum Cell Expansion System for the expansion of large numbers of MSCs from unprocessed bone marrow in a functionally closed system and compared the results with a flask-based method currently in clinical trials. Results: After only two passages, we were able to expand a mean of 6.6× 108 MSCs from 25 mL of bone marrow reproducibly. The mean expansion time was 21 days, and cells obtained were able to differentiate into all three lineages: chondrocytes, osteoblasts and adipocytes. The Quantum was able to generate the target cell number of 2.0× 108 cells in an average of 9 fewer days and in half the number of passages required during flask-based expansion. We estimated that the Quantum would involve 133 open procedures versus 54,400 in flasks when manufacturing for a clinical trial. Quantum-expanded MSCs infused into an ischemic stroke rat model were therapeutically active. Conclusions: The Quantum is a novel method of generating high numbers of MSCs in less time and at lower passages when compared with flasks. In the Quantum, the risk of contamination is substantially reduced because of the substantial decrease in open procedures.
KW - Cell culture expansion
KW - Good manufacturing practices
KW - Mesenchymal stromal cells
KW - Quantum
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=84903814743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903814743&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2014.01.417
DO - 10.1016/j.jcyt.2014.01.417
M3 - Article
C2 - 24726657
AN - SCOPUS:84903814743
SN - 1465-3249
VL - 16
SP - 1048
EP - 1058
JO - Cytotherapy
JF - Cytotherapy
IS - 8
ER -